NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,777.70+₹16.70 (+0.95%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.15% below the high.
Loading market information…
NSE · METROPOLIS.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 09:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Metropolis Healthcare Limited’s quoted price sits in the upper half of its reported 52-week range, 10.2% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Metropolis Healthcare Limited’s forward annual dividend is ₹2.00 per share, paid semi-annual. The forward yield is 0.37% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Metropolis Healthcare Limited’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of ₹3.34. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Metropolis Healthcare Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Metropolis Healthcare Limited functions as a prominent diagnostic service provider throughout India. The company delivers a comprehensive array of clinical laboratory testing, specialized diagnostic profiles, and associated support services. Its capabilities span diverse medical fields, encompassing oncology, neurology, gynecology, and nephrology. Furthermore, Metropolis offers a variety of health check-up packages specifically tailored for different demographic groups, including men, women, senior citizens, youth, and corporate clients. These tests are vital for disease prediction, early identification, diagnostic screening, confirmation, and continuous monitoring. Beyond its core diagnostic offerings, the company also extends its expertise to corporate wellness programs, hospital laboratory management solutions, and clinical research. As of March 31, 2022, Metropolis had established an extensive network comprising 171 clinical laboratories, 9,000 sample collection points, and 704 assisted referral centers. Founded in 1980, the company's corporate headquarters are situated in Mumbai, India.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:01 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 | May 13, 2025 | ₹2.17+9.6% vs estimate | ₹3.45B-2.82% vs estimate |
|---|
| Q3 2025 | Feb 4, 2025 | ₹1.53-14.53% vs estimate | ₹3.23B-0.7% vs estimate |
|---|
| Q2 2025 | Nov 8, 2024 | ₹9.03-0.22% vs estimate | ₹3.50B+0.33% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,777.70+₹16.70 (+0.95%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 13.15% below the high.
₹1,907.20-₹4.50 (-0.24%)
Dr. Lal PathLabs Limited’s quoted price sits in the upper half of its reported 52-week range, 6.45% below the high.
₹1,466.50+₹2.30 (+0.16%)
Vijaya Diagnostic Centre Limited’s quoted price sits in the upper half of its reported 52-week range, 7.98% below the high.
₹455.15-₹60.35 (-11.71%)
Thyrocare Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 31.25% below the high.
₹485.60-₹34.20 (-6.58%)
Vimta Labs Limited’s quoted price sits in the lower half of its reported 52-week range, 33.93% below the high.
₹315.50-₹4.05 (-1.27%)
Suraksha Diagnostic Ltd.’s quoted price sits in the upper half of its reported 52-week range, 12.36% below the high.
₹506.00+₹8.05 (+1.62%)
Krsnaa Diagnostics Limited’s quoted price sits in the lower half of its reported 52-week range, 39.62% below the high.
₹133.80+₹6.35 (+4.98%)
Aspira Pathlab & Diagnostics Limited’s quoted price sits in the upper half of its reported 52-week range, 10.79% below the high.
